[go: up one dir, main page]

CA2199642A1 - Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine - Google Patents

Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine

Info

Publication number
CA2199642A1
CA2199642A1 CA002199642A CA2199642A CA2199642A1 CA 2199642 A1 CA2199642 A1 CA 2199642A1 CA 002199642 A CA002199642 A CA 002199642A CA 2199642 A CA2199642 A CA 2199642A CA 2199642 A1 CA2199642 A1 CA 2199642A1
Authority
CA
Canada
Prior art keywords
aspirin
oligosaccharide
association
combination
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002199642A
Other languages
English (en)
Other versions
CA2199642C (fr
Inventor
Roger Cariou
Jacobus Christianus Johannes Stiekema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi SA
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Akzo Nobel NV filed Critical Sanofi SA
Priority to CA002199642A priority Critical patent/CA2199642C/fr
Priority to EA199700025A priority patent/EA000048B1/ru
Priority to AU16319/97A priority patent/AU698456B2/en
Priority to BR9701313A priority patent/BR9701313A/pt
Publication of CA2199642A1 publication Critical patent/CA2199642A1/fr
Application granted granted Critical
Publication of CA2199642C publication Critical patent/CA2199642C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002199642A 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine Expired - Lifetime CA2199642C (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002199642A CA2199642C (fr) 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
EA199700025A EA000048B1 (ru) 1997-03-10 1997-03-13 Применение олигосахарида и аспирина для лечения тромбоэболических заболеваний, фармацевтическая композиция, способ лечения
AU16319/97A AU698456B2 (en) 1997-03-10 1997-03-14 Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
BR9701313A BR9701313A (pt) 1997-03-10 1997-03-17 Composições que contêm uma associação de aspririna e um oligossacarídeo anti-xa e uso de um olissacarídeo anti-xa opicionalmente em combinação com aspirina

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002199642A CA2199642C (fr) 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
AU16319/97A AU698456B2 (en) 1997-03-10 1997-03-14 Compositions containing an association of aspirin and an anti-Xa oligosaccharide and use of anti-Xa oligosaccharide optionally in combination with aspirin
BR9701313A BR9701313A (pt) 1997-03-10 1997-03-17 Composições que contêm uma associação de aspririna e um oligossacarídeo anti-xa e uso de um olissacarídeo anti-xa opicionalmente em combinação com aspirina

Publications (2)

Publication Number Publication Date
CA2199642A1 true CA2199642A1 (fr) 1998-09-10
CA2199642C CA2199642C (fr) 2001-05-08

Family

ID=27152254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002199642A Expired - Lifetime CA2199642C (fr) 1997-03-10 1997-03-10 Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine

Country Status (4)

Country Link
AU (1) AU698456B2 (fr)
BR (1) BR9701313A (fr)
CA (1) CA2199642C (fr)
EA (1) EA000048B1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP2005509007A (ja) * 2001-11-13 2005-04-07 サノフィ−アベンティス Ａｃｓの治療のためのフォンダパリヌックスナトリウムの特定投与量の使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2564468B1 (fr) * 1984-05-16 1994-12-23 Choay Sa Nouveaux oligosaccharides, leur preparation par voie de synthese et leurs applications biologiques
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
JP2005509007A (ja) * 2001-11-13 2005-04-07 サノフィ−アベンティス Ａｃｓの治療のためのフォンダパリヌックスナトリウムの特定投与量の使用

Also Published As

Publication number Publication date
BR9701313A (pt) 1998-11-17
EA000048B1 (ru) 1998-04-30
AU1631997A (en) 1998-09-17
AU698456B2 (en) 1998-10-29
CA2199642C (fr) 2001-05-08
EA199700025A1 (ru) 1997-12-30

Similar Documents

Publication Publication Date Title
CA2289717A1 (fr) Nouveau traitement de la constipation
CA2274074A1 (fr) Nouveaux composes a effet analgesique
CA2392879A1 (fr) Derive de pyrrolidine acetamide seul ou combine pour traiter des affections du snc
CA2062973A1 (fr) Therapie combinee pour la prophylaxie et/ou le traitement de l'hyperplasie benigne de la prostate
CA2239174A1 (fr) Nouveaux composes a effet analgesique
CA2161641A1 (fr) Compositions therapeutiques stables a base de nadh et nadph, pouvant etre ingerees et absorbees
GEP20022851B (en) Flash-Melt Oral Dosage Formulation
UA70919C2 (uk) Композиція для лікування та запобігання артеріальному тромбозу з використанням інгібітора фактора ха окремо або в комбінації з препаратом, що унеможливлює агрегацію тромбоцитів
CA2258920A1 (fr) Acide hyaluronique autoreticule et compositions pharmaceutiques associees pour le traitement des arthropathies
CA2004239A1 (fr) Utilisation de l'acetyl-d-carnitine dans le traitement therapeutique du glaucome et composes pharmaceutiques utiles dans un tel traitement
CA2214097A1 (fr) Emploi de ketorolac pour le traitement d'epithelioma spinocellulaires de la cavite buccale ou de l'arriere gorge
EP0513702A3 (fr) Dérivés de la mélatonine utiles dans le traitement des troubles du sommeil et en pré-anesthésie
CA2200754A1 (fr) Procede de fabrication d'unites posologiques au moyen d'une granulation par voie humide
CA2343732A1 (fr) .delta.-lactones .gamma.-phenyl-substituees, leurs analogues, et leurs utilisations
AU8188691A (en) The use of inositoltrisphosphate for the preparing of medicaments
BG104434A (en) 2-halo-6-o-substituted ketolide derivatives
PL323617A1 (en) Pharmaceutical preparation for treating oestrogen-dependent carcinomas
CA2108963A1 (fr) Compositions et methodes de traitement et de prevention du cancer, du sida et de l'anemie
WO1999061010A3 (fr) TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE
CA2202397A1 (fr) Compositions comprenant de l'acide dichloroacetique tamponne au carbonate/bicarbonate et procedes de traitement de troubles metaboliques et cardiovasculaires
EP2138175A3 (fr) Formulations comprenant du valsartan pour traiter le diabète ou la microalbuminurie
CA2132544A1 (fr) Antagonistes d'angiotensine ii utiles contre les troubles lies a une vitesse alteree de l'influx nerveux, particulierement dans le cas de la neuropathie diabetique
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
CA2199642A1 (fr) Compositions associant l'aspirine et un oligosaccharide anti-xa et utilisation d'un oligosaccharide anti-xa facultativement associe a l'aspirine
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170310